Retension Pharmaceuticals Inc
As-reported results for the 2 quarters ended Dec 31, 2025 to Jun 30, 2026
RETENSION PHARMACEUTICALS INC (RTSN)'s financial overview covers its 2 most recent reported quarters, with quarter-end dates from 2025-12-31 to 2026-06-30.
1Trends2 quarters · Dec ’25 to Jun ’26
2Income statementUSD, as reported
| Metric | Jun ’26 | Dec ’25 |
|---|---|---|
| Revenue | — | — |
| Cost of revenue | — | — |
| Gross profit | — | — |
| Operating expenses | — | — |
| Research and development | — | — |
| Selling, general and administrative | — | — |
| Operating income | — | — |
| Interest expense | — | — |
| Income before tax | — | — |
| Income tax expense | — | — |
| Net income | — | — |
| Net income attributable to common shareholders | — | — |
| EBIT | — | — |
| EBITDA | — | — |
| Basic earnings per share | — | — |
| Diluted earnings per share | — | — |
| Weighted-average basic sharesshares | 807K | 5M |
| Weighted-average diluted sharesshares | — | — |
3Balance sheetUSD, as reported
| Metric | Jun ’26 | Dec ’25 |
|---|---|---|
| Total assets | $16.13M | $21.45M |
| Current assets | $16.13M | $21.45M |
| Cash and cash equivalents | $13.49M | $18.9M |
| Total liabilities | $2.88M | $912.17K |
| Current liabilities | $2.88M | $912.17K |
| Total debt | $0 | $0 |
| Current debt | $0 | $0 |
| Equity attributable to parent | −$14.92M | −$7.78M |
4Cash flowUSD, as reported
| Metric | Jun ’26 | Dec ’25 |
|---|---|---|
| Operating cash flow | — | — |
| Investing cash flow | — | — |
| Financing cash flow | — | — |
| Net capital expenditures (acquisitions and disposals) | — | — |
| Free cash flow | — | — |
| Stock-based compensation | — | — |
5About these figures
At the latest quarter-end, 2026-06-30, the company reported cash and cash equivalents of USD 13.49M and total debt of USD 0. The tables below compare income statements, balance sheets and cash flows across all 2 quarters, with individual quarterly results available for further detail.
Figures are as reported in the company's quarterly filings for its 2 most recent reported quarters, up to 10 quarters per listing, newest first. Each quarter reflects the latest filed version of that quarter's statements; restated figures replace the originally reported ones. Per-share amounts are shown per share and share counts are weighted averages for the quarter. A dash marks a metric the company did not report for that quarter.